Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial - Fizazi, Karim; Retz, Margitta; Petrylak, Daniel P.; Goh, Jeffrey C.; Perez-Gracia, Jose; Lacombe, Louis; Zschäbitz, Stefanie; Burotto, Mauricio; Mahammedi, Hakim; Gravis, Gwenaelle; Bastos, Diogo Assed; McCune, Steven L.; et al. (Journal for ImmunoTherapy of Cancer, 2022)
Gesehen am 22.11.2022